You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
同源康醫藥(02410.HK)發布艾多替尼片非小細胞肺癌II期臨床試驗結果
阿思達克 08-14 08:22
同源康醫藥(02410.HK)表示,自主研發的創新藥物艾多替尼片(TY-9591)治療EGFR變異型非小細胞肺癌(NSCLC)的關鍵性II期註冊臨床試驗(NCT05948813)結果,已在國際肺癌研究協會(IASLC)舉辦的2025年世界肺癌會議(WCLC)上被接受為minioral報告(MA08.06),並將在會議期間進行專題匯報。 艾多替尼片(TY-9591)是公司開發的高選擇性小分子抑制劑,以經典EGFR基因突變為靶點,旨在滿足在當前治療標準下對非小細胞肺癌腦轉移瘤尚未得到滿足的臨床需求。研究表明,艾多替尼作為研發的新一代EGFR-TKI,對控制腦轉移病灶和緩解病情顯示優異的療效,有望為伴腦轉移的EGFR突變NSCLC患者提供新的、更有效的一線治療選擇。 公司表示,研究團隊將持續跟進,以獲取成熟的iPFS、PFS及OS數據,推動該創新藥盡快造福患者。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account